SMMC is accredited by
The Joint Commission
One of 93 hospitals nationwide
so designated by the
American Nurses Credentialing Center
SMMC's Cancer Program has received
Accreditation with Commendation,
the highest level awarded
Crucial in the development of drugs, clinical trials are today delayed by the difficulty of recruiting participants. Decentralize and dematerialize, thanks to digital, could be the solution.
Why digitize clinical trials?
Lionel Bascles. - The organization of clinical trials has become more complex, time consuming and expensive. Recruiting appropriate participants is increasingly difficult, especially when it comes to treatments targeting very specific diseases that only affect small populations of patients cialisfr.fr.
Remy Chossinand. - Another barrier to patient participation is geographic location. 87% of patients wish to participate in clinical trials. Many of them live more than two hours away from the nearest study site. Knowing that most of the time, participation in clinical trials requires patients to travel for regular observations and examinations, sometimes several times a month, it goes without saying that their distance from the study site represents a significant obstacle in terms of of participation. 80% of clinical studies are delayed because of recruitment problems.
LB. - These delays, which prolong the period of development of new innovative drugs, de facto delay their marketing, so much so that patients often have to wait for many years to benefit from new therapeutic options. In order to remedy this growing problem, Sanofi is working on developing new solutions around decentralization and dematerialization of the conduct of its clinical trials, thanks to digital technology.
What benefits does this digitization of digital tests bring?
RC. - The use of digital technologies to streamline participant identification, recruitment and retention of participants in the study is expected to reduce the duration of standard clinical trials by at least 30% 2. Patients will, for example, be able to be tracked and transmit the data of this follow-up to the researchers thanks to a smartphone. They will be able to communicate with the study staff at any time, while continuing to be cared for by their attending physician. Patient data will then be sent securely to researchers.
RC. - With "digital" clinical trials, data on the effect of a new drug in a real-life situation can be obtained and analyzed much earlier, which will allow patients to have faster access to medicines.
Why is this practice undeveloped in France?
LB. - This is not peculiar to the Hexagon. France is no more behind than its neighbors in the development of digital tools. It even has many strengths: excellent engineering courses, creative and innovative projects acclaimed abroad, clear strategic directions in terms of artificial intelligence, etc. The development of telemedicine in France as well as the creation and use of more and more frequent digital medical data (e-MR) platforms are, with medical excellence, important levers in the project of transformation of clinical trials.
Improving clinical research also involves everyone's commitment. We must be part of it, agree to contribute to the development of new health solutions. This can mean participating in a clinical trial or simply agreeing to share its health data (which will be anonymised), subject of course to strict compliance with laws on access and use of personal data. Only under these conditions will we advance research for the benefit of patients.
Glen Solsberg, 304-283-9998